Sandbox: TAVI - AUC: Difference between revisions
Arzu Kalayci (talk | contribs) |
Arzu Kalayci (talk | contribs) |
||
(19 intermediate revisions by the same user not shown) | |||
Line 16: | Line 16: | ||
|- | |- | ||
| - LVEF ≤50% | | - LVEF ≤50% | ||
- Vmax 4.0–4.9 m/sec | - Vmax 4.0–4.9 m/sec | ||
- No predictors of symptom onset or of rapid progression (e.g., DVmax >0.3 m/s/y, severe valve calcification, elevated BNP, or excessive LV hypertrophy in the absence of hypertension) | - Negative exercise stress test | ||
- No predictors of symptom onset or of rapid progression (e.g., DVmax >0.3 m/s/y, severe valve calcification, elevated BNP, or excessive LV hypertrophy in the absence of hypertension) | |||
- High or intermediate surgical risk | |||
| bgcolor="LightGreen" | A (7) || bgcolor="LemonChiffon" | M (5) | | bgcolor="LightGreen" | A (7) || bgcolor="LemonChiffon" | M (5) | ||
|- | |- | ||
| - LVEF ≤50% | | - LVEF ≤50% | ||
- Vmax 4.0–4.9 m/sec | - Vmax 4.0–4.9 m/sec | ||
- No predictors of symptom onset or of rapid progression (e.g., DVmax >0.3 m/s/y, severe valve calcification, elevated BNP, or excessive LV hypertrophy in the absence of hypertension) | - Negative exercise stress test | ||
- No predictors of symptom onset or of rapid progression (e.g., DVmax >0.3 m/s/y, severe valve calcification, elevated BNP, or excessive LV hypertrophy in the absence of hypertension) | |||
- Low surgical risk | |||
| bgcolor="LightGreen" | A (7) || bgcolor="LemonChiffon" | M (5) | | bgcolor="LightGreen" | A (7) || bgcolor="LemonChiffon" | M (5) | ||
|- | |- | ||
| - LVEF ≥50% | | - LVEF ≥50% | ||
- Vmax 4.0–4.9 m/sec | - Vmax 4.0–4.9 m/sec | ||
- High-risk profession (e.g., airline pilot) or lifestyle (e.g., competitive athlete) or anticipated prolonged time away from close medical supervision | |||
- Low surgical risk | - Low surgical risk | ||
Line 34: | Line 44: | ||
|- | |- | ||
| - LVEF ≥50% | | - LVEF ≥50% | ||
- Vmax 4.0–4.9 m/sec | - Vmax 4.0–4.9 m/sec | ||
- High-risk profession (e.g., airline pilot) or lifestyle (e.g., competitive athlete) or anticipated prolonged time away from close medical supervision | |||
- Low surgical risk | - Low surgical risk | ||
Line 40: | Line 52: | ||
|- | |- | ||
| - LVEF ≥50% | | - LVEF ≥50% | ||
- Vmax 4.0–4.9 m/sec | - Vmax 4.0–4.9 m/sec | ||
- Negative exercise stress test | |||
- ≥1 predictor(s) of symptom onset or of rapid progression (e.g., DVmax >0.3 m/s/y, severe valve calcification, elevated BNP, or excessive LV hypertrophy in the absence of hypertension) | |||
- High or intermediate surgical risk | |||
| bgcolor="LemonChiffon" | M (4) || bgcolor="LightGreen" | A (7) | | bgcolor="LemonChiffon" | M (4) || bgcolor="LightGreen" | A (7) | ||
|- | |- | ||
| - LVEF ≥50% | | - LVEF ≥50% | ||
- Vmax 4.0–4.9 m/sec | - Vmax 4.0–4.9 m/sec | ||
- ≥1 predictor(s) of symptom onset or of rapid progression (e.g., DVmax >0.3 m/s/y, severe valve calcification, elevated BNP, or excessive LV hypertrophy in the absence of hypertension) | - Negative exercise stress test | ||
- ≥1 predictor(s) of symptom onset or of rapid progression (e.g., DVmax >0.3 m/s/y, severe valve calcification, elevated BNP, or excessive LV hypertrophy in the absence of hypertension) | |||
- Low surgical risk | |||
| bgcolor="LemonChiffon" | M (4) || bgcolor="LightGreen" | A (8) | | bgcolor="LemonChiffon" | M (4) || bgcolor="LightGreen" | A (8) | ||
|- | |- | ||
| - LVEF ≥50% - Vmax 4.0–4.9 m/sec | | - LVEF ≥50% | ||
- Abnormal exercise stress test | - Vmax 4.0–4.9 m/sec | ||
- Abnormal exercise stress test | |||
- High or intermediate surgical risk | |||
| bgcolor="LightCoral" | R (3) || bgcolor="LightGreen" | A (8) | | bgcolor="LightCoral" | R (3) || bgcolor="LightGreen" | A (8) | ||
|- | |- | ||
| - LVEF ≥50% | | - LVEF ≥50% | ||
- Vmax 4.0–4.9 m/sec | - Vmax 4.0–4.9 m/sec | ||
- Abnormal exercise stress test | |||
- Low surgical risk | - Low surgical risk | ||
Line 62: | Line 87: | ||
|- | |- | ||
| - LVEF ≥50% | | - LVEF ≥50% | ||
- Very severe AS (Vmax ≥5 m/sec or mean gradient ≥60 mmHg) | - Very severe AS (Vmax ≥5 m/sec or mean gradient ≥60 mmHg) | ||
- High or intermediate surgical risk | |||
| bgcolor="LemonChiffon" | M (4) || bgcolor="LightGreen" | A (7) | | bgcolor="LemonChiffon" | M (4) || bgcolor="LightGreen" | A (7) | ||
|- | |- | ||
| - LVEF ≥50% | | - LVEF ≥50% | ||
- Very severe AS (Vmax ≥5 m/sec or mean gradient ≥60 mmHg) | - Very severe AS (Vmax ≥5 m/sec or mean gradient ≥60 mmHg) | ||
- Low surgical risk | |||
| bgcolor="LightCoral" | R (2) || bgcolor="LightGreen" | A (8) | | bgcolor="LightCoral" | R (2) || bgcolor="LightGreen" | A (8) | ||
|- | |- | ||
| - LVEF <50% | | - LVEF <50% | ||
- Very severe AS (Vmax ≥4 m/sec or mean gradient ≥40 mmHg) | - Very severe AS (Vmax ≥4 m/sec or mean gradient ≥40 mmHg) | ||
- High or intermediate surgical risk | |||
| bgcolor="LightCoral" | R (2) || bgcolor="LightGreen" | A (8) | | bgcolor="LightCoral" | R (2) || bgcolor="LightGreen" | A (8) | ||
|- | |- | ||
| - LVEF <50% | | - LVEF <50% | ||
- Very severe AS (Vmax ≥4 m/sec or mean gradient ≥40 mmHg) | - Very severe AS (Vmax ≥4 m/sec or mean gradient ≥40 mmHg) | ||
- Low surgical risk | |||
| bgcolor="LightCoral" | R (1) || bgcolor="LightGreen" | A (9) | | bgcolor="LightCoral" | R (1) || bgcolor="LightGreen" | A (9) | ||
|- | |- | ||
Line 95: | Line 128: | ||
|- | |- | ||
| - AVA ≤1.0 cm2 (or indexed AVA ≤0.6 cm2/m2) on resting echo | | - AVA ≤1.0 cm2 (or indexed AVA ≤0.6 cm2/m2) on resting echo | ||
- LVEF 20% to 49% | - LVEF 20% to 49% | ||
- Low | - Low flow | ||
- Truly severe AS - High or intermediate surgical risk | - Low gradient | ||
| | |||
- Flow reserve on low-dose dobutamine echo | |||
- Truly severe AS | |||
- High or intermediate surgical risk | |||
| bgcolor="LightCoral" | R (1) || bgcolor="LightCoral" | R (3) || bgcolor="LightGreen" | A (8) | |||
|- | |- | ||
| - AVA ≤1.0 cm2 (or indexed AVA ≤0.6 cm2/m2) on resting echo | | - AVA ≤1.0 cm2 (or indexed AVA ≤0.6 cm2/m2) on resting echo | ||
- LVEF 20% to 49% | - LVEF 20% to 49% | ||
- Low | - Low flow | ||
- Truly severe AS | - Low gradient | ||
| | |||
- Flow reserve on low-dose dobutamine echo | |||
- Truly severe AS | |||
- Low surgical risk | |||
| bgcolor="LightCoral" | R (1) || bgcolor="LightCoral" | R (2) || bgcolor="LightGreen" | A (9) | |||
|- | |- | ||
| - AVA ≤1.0 cm2 (or indexed AVA ≤0.6 cm2/m2) on resting echo | | - AVA ≤1.0 cm2 (or indexed AVA ≤0.6 cm2/m2) on resting echo | ||
- LVEF 20% to 49% | - LVEF 20% to 49% | ||
- Low flow | |||
- Low gradient | |||
- Flow reserve on low-dose dobutamine echo | |||
- Pseudosevere AS | - Pseudosevere AS | ||
| | | bgcolor="LightGreen" | A (8) || bgcolor="LightCoral" | R (2) || bgcolor="LightCoral" | R (2) | ||
|- | |- | ||
| - AVA ≤1.0 cm2 (or indexed AVA ≤0.6 cm2/m2) on resting echo | | - AVA ≤1.0 cm2 (or indexed AVA ≤0.6 cm2/m2) on resting echo | ||
- LVEF 20% to 49% - Low flow | - LVEF 20% to 49% | ||
- Low flow | |||
- Low gradient | |||
- No flow reserve on low-dose dobutamine echo | |||
- | - Very calcified aortic valve on echo and/or CT, suggesting truly severe AS, or calculation of a projected valve area that remains severely reduced | ||
- High or intermediate surgical risk | |||
| | | bgcolor="LemonChiffon" | M (4) || bgcolor="LemonChiffon" | M (5) || bgcolor="LightGreen" | A (7) | ||
|- | |- | ||
| - AVA ≤1.0 cm2 (or indexed AVA ≤0.6 cm2/m2) on resting echo | | - AVA ≤1.0 cm2 (or indexed AVA ≤0.6 cm2/m2) on resting echo | ||
- LVEF 20% to 49% | - LVEF 20% to 49% | ||
- Low | - Low flow | ||
- Minimal calcification on aortic valve on echo and/or CT | - Low gradient | ||
| | |||
- No flow reserve on low-dose dobutamine echo | |||
- Minimal calcification on aortic valve on echo and/or CT | |||
- High or intermediate surgical risk | |||
| bgcolor="LightGreen" | A (7) || bgcolor="LightCoral" | R (3) || bgcolor="LightCoral" | R (2) | |||
|- | |- | ||
| - AVA ≤1.0 cm2 (or indexed AVA ≤0.6 cm2/m2) | | - AVA ≤1.0 cm2 (or indexed AVA ≤0.6 cm2/m2) | ||
- LVEF <20% | - LVEF <20% | ||
- Vmax ≥4 m/sec or mean gradient ≥40 mmHg on resting echo | |||
- High or intermediate surgical risk | - High or intermediate surgical risk | ||
| | | bgcolor="LightCoral" | R (3) || bgcolor="LemonChiffon" | M (4) || bgcolor="LightGreen" | A (7) | ||
|- | |- | ||
| - AVA ≤1.0 cm2 (or indexed AVA ≤0.6 cm2/m2) | | - AVA ≤1.0 cm2 (or indexed AVA ≤0.6 cm2/m2) | ||
- LVEF <20% | - LVEF <20% | ||
- No flow reserve on low-dose dobutamine echo - High or intermediate surgical risk | - Mean gradient <20 mmHg on resting echo | ||
| | |||
- No flow reserve on low-dose dobutamine echo | |||
- High or intermediate surgical risk | |||
| bgcolor="LightGreen" | A (7) || bgcolor="LemonChiffon" | M (4) || bgcolor="LightCoral" | R (3) | |||
|- | |- | ||
| - AVA ≤1.0 cm2 (or indexed AVA ≤0.6 cm2/m2) on resting echo | | - AVA ≤1.0 cm2 (or indexed AVA ≤0.6 cm2/m2) on resting echo | ||
- LVEF <20% | - LVEF <20% | ||
- Low | - Low flow | ||
- Truly severe AS | - Low gradient | ||
| | |||
- Flow reserve on low-dose dobutamine echo | |||
- Truly severe AS | |||
- High or intermediate surgical risk | |||
| bgcolor="LightCoral" | R (3) || bgcolor="LemonChiffon" | M (5) || bgcolor="LightGreen" | A (7) | |||
|- | |- | ||
| - AVA ≤1.0 cm2 (or indexed AVA ≤0.6 cm2/m2) on resting echo | | - AVA ≤1.0 cm2 (or indexed AVA ≤0.6 cm2/m2) on resting echo | ||
- LVEF <20% | - LVEF <20% | ||
- Low flow | |||
- Low gradient | - Low gradient | ||
- Pseudosevere severe AS | - Flow reserve on low-dose dobutamine echo | ||
| | |||
- Pseudosevere severe AS | |||
- High or intermediate surgical risk | |||
| bgcolor="LightGreen" | A (7) || bgcolor="LightCoral" | R (2) || bgcolor="LightCoral" | R (2) | |||
|- | |- | ||
| '''Preserved Ejection Fraction (≥50%)''' | | colspan="4" | '''Preserved Ejection Fraction (≥50%)''' | ||
|- | |- | ||
| - AVA ≤1.0 cm2 (or indexed AVA ≤0.6 cm2/m2) | | - AVA ≤1.0 cm2 (or indexed AVA ≤0.6 cm2/m2) | ||
- Vmax ≥4 m/sec or mean gradient ≥40 mmHg on resting echo | - Vmax ≥4 m/sec or mean gradient ≥40 mmHg on resting echo | ||
- Symptomatic | |||
- High or intermediate surgical risk | - High or intermediate surgical risk | ||
Line 171: | Line 252: | ||
|- | |- | ||
| - AVA ≤1.0 cm2 (or indexed AVA ≤0.6 cm2/m2) | | - AVA ≤1.0 cm2 (or indexed AVA ≤0.6 cm2/m2) | ||
- Vmax ≥4 m/sec or mean gradient ≥40 mmHg on resting echo | - Vmax ≥4 m/sec or mean gradient ≥40 mmHg on resting echo | ||
- Symptomatic | |||
- Low surgical risk | - Low surgical risk | ||
Line 179: | Line 262: | ||
- Low flow - Low gradient - Symptomatic | - Low flow - Low gradient - Symptomatic | ||
- Evidence of a severely calcified valve | - Evidence of a severely calcified valve | ||
- Clinical, hemodynamic, and anatomic data support valve obstruction as the most likely cause of symptoms | |||
- High or intermediate surgical risk | - High or intermediate surgical risk | ||
Line 185: | Line 270: | ||
|- | |- | ||
| - AVA ≤1.0 cm2 (or indexed AVA ≤0.6 cm2/m2) | | - AVA ≤1.0 cm2 (or indexed AVA ≤0.6 cm2/m2) | ||
- Low flow | - Low flow | ||
- Low gradient | |||
- Symptomatic | |||
- Evidence of a severely calcified valve | |||
- | - Clinical, hemodynamic, and anatomic data support valve obstruction as the most likely cause of symptoms | ||
- Low surgical risk | |||
| bgcolor="LightCoral" | R (1) || bgcolor="LightCoral" | R (1) || bgcolor="LightGreen" | A (9) | | bgcolor="LightCoral" | R (1) || bgcolor="LightCoral" | R (1) || bgcolor="LightGreen" | A (9) | ||
|- | |- | ||
| - AVA ≤1.0 cm2 (or indexed AVA ≤0.6 cm2/m2) | | - AVA ≤1.0 cm2 (or indexed AVA ≤0.6 cm2/m2) | ||
- Low flow | - Low flow | ||
- Low gradient | |||
- Evidence of a severely calcified valve | |||
- Asymptomatic | |||
- High or intermediate surgical risk | - High or intermediate surgical risk | ||
Line 201: | Line 296: | ||
|- | |- | ||
| - AVA ≤1.0 cm2 (and indexed AVA ≤0.6 cm2/m2) | | - AVA ≤1.0 cm2 (and indexed AVA ≤0.6 cm2/m2) | ||
- Low gradient | - Low gradient | ||
- Evidence of a severely calcified valve | - Low flow | ||
- Evidence of a severely calcified valve | |||
- Asymptomatic | |||
- Low surgical risk | - Low surgical risk | ||
Line 209: | Line 308: | ||
|- | |- | ||
| - AVA ≤1.0 cm2 (and indexed AVA ≤0.6 cm2/m2) | | - AVA ≤1.0 cm2 (and indexed AVA ≤0.6 cm2/m2) | ||
- Normal flow | - Normal flow | ||
- | - Low gradient | ||
- Symptoms believed to be due to AS | - Confirmation of internal consistency of the AVA, flow, and gradient measurements | ||
- Evidence of a severely calcified valve | |||
- Symptoms believed to be due to AS | |||
- High or intermediate surgical risk | |||
| bgcolor="LightCoral" | R (3) || bgcolor="LemonChiffon" | M (4) || bgcolor="LightGreen" | A (7) | | bgcolor="LightCoral" | R (3) || bgcolor="LemonChiffon" | M (4) || bgcolor="LightGreen" | A (7) | ||
|- | |- | ||
| - AVA ≤1.0 cm2 (and indexed AVA ≤0.6 cm2/m2) | | - AVA ≤1.0 cm2 (and indexed AVA ≤0.6 cm2/m2) | ||
- Normal flow | - Normal flow | ||
- Low gradient | |||
- Confirmation of internal consistency of the AVA, flow, and gradient measurements | - Confirmation of internal consistency of the AVA, flow, and gradient measurements | ||
- Symptoms believed to be due to AS | - Evidence of a severely calcified valve | ||
- Symptoms believed to be due to AS | |||
- Low surgical risk | |||
| bgcolor="LightCoral" | R (3) || bgcolor="LightCoral" | R (3) || bgcolor="LightGreen" | A (7) | | bgcolor="LightCoral" | R (3) || bgcolor="LightCoral" | R (3) || bgcolor="LightGreen" | A (7) | ||
|- | |- | ||
| colspan="4" | '''A''' = Appropriate; '''AS''' = aortic stenosis; '''AVA''' = aortic valve area; '''AVR''' = aortic valve replacement; '''BAV''' = balloon aortic valvuloplasty; '''CT''' = computed tomography; '''LVEF''' = left ventricular ejection fraction; '''M''' = May Be Appropriate; '''R''' = Rarely Appropriate; '''SAVR''' = surgical aortic valve replacement; '''TAVR''' = transcatheter aortic valve replacement; '''Vmax''' = peak aortic valve velocity. | | colspan="4" | '''A''' = Appropriate; '''AS''' = aortic stenosis; '''AVA''' = aortic valve area; '''AVR''' = aortic valve replacement; '''BAV''' = balloon aortic valvuloplasty; '''CT''' = computed tomography; '''LVEF''' = left ventricular ejection fraction; '''M''' = May Be Appropriate; '''R''' = Rarely Appropriate; '''SAVR''' = surgical aortic valve replacement; '''TAVR''' = transcatheter aortic valve replacement; '''Vmax''' = peak aortic valve velocity. | ||
|} | |||
===Severe AS: High- or Extreme-Risk Patients=== | |||
===Appropriate Use Median Score (1–9)=== | |||
{| class="wikitable" style="width: 80%; text-align: justify;" | |||
! style="width:70%" | '''Indication''' | |||
! style="width:10%" | '''No Intervention''' | |||
! style="width:10%" | '''BAV (as Bridge to Decision)''' | |||
! style="width:10%" | '''TAVR''' | |||
! style="width:10%" | '''SAVR''' | |||
|- | |||
| '''Due to Multiple Comorbidities''' || || || || | |||
|- | |||
| - Severe symptomatic AS | |||
- STS-PROM 8%–15% | |||
- Health status seems to be influenced more by comorbidities than by AS | |||
- Anticipated life expectancy >1 y | |||
| bgcolor="LemonChiffon" | M (4) || bgcolor="LemonChiffon" | M (5) || bgcolor="LightGreen" | A (7) || bgcolor="LemonChiffon" | M (4) | |||
|- | |||
| - Severe symptomatic AS | |||
- STS-PROM 8%–15% | |||
- Health status seems to be influenced more by AS than by comorbidities | |||
- Anticipated life expectancy >1 y | |||
| bgcolor="LightCoral" | R (2) || bgcolor="LemonChiffon" | M (4) || bgcolor="LightGreen" | A (8) || bgcolor="LemonChiffon" | M (5) | |||
|- | |||
| - Severe symptomatic AS | |||
- STS-PROM 8%–15% | |||
- Health status seems to be influenced more by comorbidities than by AS | |||
- Anticipated life expectancy <1 y | |||
| bgcolor="LightGreen" | A (8) || bgcolor="LemonChiffon" | M (5) || bgcolor="LightCoral" | R (3) || bgcolor="LightCoral" | R (1) | |||
|- | |||
| - Severe symptomatic AS | |||
- STS-PROM 8%–15% | |||
- Health status seems to be influenced more by AS than by comorbidities | |||
- Anticipated life expectancy <1 y | |||
| bgcolor="LemonChiffon" | M (6) || bgcolor="LemonChiffon" | M (5) || bgcolor="LemonChiffon" | M (4) || bgcolor="LightCoral" | R (2) | |||
|- | |||
| - Severe symptomatic AS | |||
- STS-PROM >15% | |||
- Health status seems to be influenced more by comorbidities than by AS | |||
- Anticipated life expectancy >1 y | |||
| bgcolor="LemonChiffon" | M (6) || bgcolor="LemonChiffon" | M (5) || bgcolor="LemonChiffon" | M (6) || bgcolor="LightCoral" | R (2) | |||
|- | |||
| - Severe symptomatic AS | |||
- STS-PROM >15% | |||
- Health status seems to be influenced more by AS than by comorbidities | |||
- Anticipated life expectancy >1 y | |||
| bgcolor="LemonChiffon" | M (4) || bgcolor="LemonChiffon" | M (5) || bgcolor="LightGreen" | A (7) || bgcolor="LightCoral" | R (3) | |||
|- | |||
| - Severe symptomatic AS | |||
- STS-PROM >15% | |||
- Health status seems to be influenced more by comorbidities than by AS | |||
- Anticipated life expectancy <1 y | |||
| bgcolor="LightGreen" | A (8) || bgcolor="LemonChiffon" | M (4) || bgcolor="LightCoral" | R (3) || bgcolor="LightCoral" | R (1) | |||
|- | |||
| - Severe symptomatic AS | |||
- STS-PROM >15% | |||
- Health status seems to be influenced more by AS than by comorbidities | |||
- Anticipated life expectancy <1 y | |||
| bgcolor="LightGreen" | A (7) || bgcolor="LemonChiffon" | M (5) || bgcolor="LightCoral" | R (3) || bgcolor="LightCoral" | R (1) | |||
|- | |||
| '''With Frailty or Disability''' || || || || | |||
|- | |||
| - Severe AS (Vmax 4–4.9 m/s) | |||
- STS-PROM 8%–15% | |||
- Frail | |||
- No chest pain or syncope | |||
- Fatigue but no shortness of breath | |||
- Normal BNP | |||
| bgcolor="LemonChiffon" | M (5) || bgcolor="LemonChiffon" | M (4) || bgcolor="LemonChiffon" | M (5) || bgcolor="LightCoral" | R (3) | |||
|- | |||
| - Severe AS (Vmax 4–4.9 m/s) | |||
- STS-PROM 8%–15% | |||
- Frail | |||
- No chest pain or syncope | |||
- Fatigue but no shortness of breath | |||
- BNP elevated | |||
| bgcolor="LemonChiffon" | M (4) || bgcolor="LemonChiffon" | M (4) || bgcolor="LightGreen" | A (7) || bgcolor="LemonChiffon" | M (4) | |||
|- | |||
| - Severe AS (Vmax ≥5 m/s) | |||
- STS-PROM 8%–15% | |||
- Frail | |||
- No chest pain or syncope | |||
- Fatigue but no shortness of breath | |||
- Normal BNP | |||
| bgcolor="LemonChiffon" | M (4) || bgcolor="LemonChiffon" | M (5) || bgcolor="LightGreen" | A (7) || bgcolor="LemonChiffon" | M (4) | |||
|- | |||
| - Severe AS (Vmax ≥5 m/s) | |||
- STS-PROM 8%–15% | |||
- Frail | |||
- No chest pain or syncope | |||
- Fatigue but no shortness of breath | |||
- BNP elevated | |||
| bgcolor="LightCoral" | R (3) || bgcolor="LemonChiffon" | M (5) || bgcolor="LightGreen" | A (8) || bgcolor="LemonChiffon" | M (4) | |||
|- | |||
| - Severe AS (Vmax ≥4 m/s) | |||
- STS-PROM 8%-15% | |||
- Dependent in >3 activities of daily living (bathing, dressing, eating, ambulating, toileting, transferring) | |||
- Shortness of breath | |||
| bgcolor="LemonChiffon" | M (5) || bgcolor="LemonChiffon" | M (5) || bgcolor="LemonChiffon" | M (5) || bgcolor="LightCoral" | R (2) | |||
|- | |||
| - Severe AS (Vmax ≥4 m/s) | |||
- STS-PROM 8%-15% | |||
- Dependent in >3 activities of daily living (bathing, dressing, eating, ambulating, toileting, transferring) | |||
- Fatigue but no shortness of breath | |||
| bgcolor="LemonChiffon" | M (5) || bgcolor="LemonChiffon" | M (5) || bgcolor="LemonChiffon" | M (5) || bgcolor="LightCoral" | R (2) | |||
|- | |||
| '''Due to Anatomy''' || || || || | |||
|- | |||
| - Severe symptomatic AS | |||
- Porcelain aorta or hostile chest | |||
- Otherwise high or intermediate surgical risk due to comorbidities | |||
| bgcolor="LightCoral" | R (2) || bgcolor="LemonChiffon" | M (4) || bgcolor="LightGreen" | A (8) || bgcolor="LightCoral" | R (3) | |||
|- | |||
| - Severe symptomatic AS | |||
- Porcelain aorta or hostile chest | |||
- Otherwise low surgical risk due to comorbidities | |||
| bgcolor="LightCoral" | R (1) || bgcolor="LightCoral" | R (3) || bgcolor="LightGreen" | A (8) || bgcolor="LemonChiffon" | M (4) | |||
|- | |||
| '''Due to Specific Comorbidities''' || || || || | |||
|- | |||
| - Severe AS | |||
- STS-PROM 8%–15% | |||
- Oxygen-dependent lung disease | |||
- Shortness of breath | |||
- BNP normal | |||
| bgcolor="LemonChiffon" | M (5) || bgcolor="LemonChiffon" | M (5) || bgcolor="LightGreen" | A (7) || bgcolor="LightCoral" | R (3) | |||
|- | |||
| - Severe AS | |||
- STS-PROM 8%–15% | |||
- Oxygen-dependent lung disease | |||
- Shortness of breath | |||
- BNP elevated | |||
| bgcolor="LightCoral" | R (3) || bgcolor="LemonChiffon" | M (5) || bgcolor="LightGreen" | A (8) || bgcolor="LemonChiffon" | M (4) | |||
|- | |||
| - Severe symptomatic AS | |||
- STS-PROM >15% | |||
- End-stage renal disease | |||
- Longstanding dialysis, not a renal transplant candidate | |||
- Multiple comorbidities | |||
| bgcolor="LemonChiffon" | M (5) || bgcolor="LemonChiffon" | M (4) || bgcolor="LemonChiffon" | M (6) || bgcolor="LightCoral" | R (2) | |||
|- | |||
| - Severe symptomatic AS | |||
- STS-PROM 8%–15% | |||
- End-stage renal disease | |||
- Short time on dialysis | |||
- Renal transplant candidate | |||
- Nondiabetic, nonhypertensive ethology | |||
| bgcolor="LightCoral" | R (3) || bgcolor="LightCoral" | R (3) || bgcolor="LightGreen" | A (7) || bgcolor="LightGreen" | A (7) | |||
|- | |||
| - Severe symptomatic AS | |||
- STS-PROM 8%–15% | |||
- Cirrhosis with MELD >14 | |||
| bgcolor="LemonChiffon" | M (5) || bgcolor="LemonChiffon" | M (5) || bgcolor="LightGreen" | A (7) || bgcolor="LightCoral" | R (2) | |||
|- | |||
| - Severe symptomatic AS | |||
- STS-PROM 8%–15% | |||
- Cirrhosis with MELD <10 | |||
| bgcolor="LightCoral" | R (3) || bgcolor="LemonChiffon" | M (4) || bgcolor="LightGreen" | A (7) || bgcolor="LemonChiffon" | M (5) | |||
|- | |||
| - Severe symptomatic AS | |||
- STS-PROM 8%–15% | |||
- Moderate to severe dementia (minimally oriented) | |||
- Symptoms described by family but not verbalized by the patient | |||
| bgcolor="LightGreen" | A (8) || bgcolor="LightCoral" | R (3) || bgcolor="LightCoral" | R (2) || bgcolor="LightCoral" | R (1) | |||
|- | |||
| - Severe symptomatic AS | |||
- STS-PROM 8%–15% | |||
- Malignancy | |||
- Life expectancy >1 year | |||
| bgcolor="LemonChiffon" | M (5) || bgcolor="LemonChiffon" | M (4) || bgcolor="LightGreen" | A (7) || bgcolor="LemonChiffon" | M (6) | |||
|- | |||
| - Severe symptomatic AS | |||
- STS-PROM 8%–15% | |||
- Malignancy | |||
- Life expectancy <1 year | |||
| bgcolor="LightGreen" | A (7) || bgcolor="LemonChiffon" | M (5) || bgcolor="LightCoral" | R (2) || bgcolor="LightCoral" | R (1) | |||
|- | |||
| colspan="5" | '''A''' = Appropriate; '''AS''' = aortic stenosis; '''BAV''' = balloon aortic valvuloplasty; '''BNP''' = b-type natriuretic peptide; '''M''' = May Be Appropriate; '''MELD''' = model for end-stage liver disease; '''R''' = Rarely Appropriate; '''SAVR''' = surgical aortic valve replacement; '''STS-PROM''' = Society of Thoracic Surgeons predicted risk of mortality score; '''TAVR''' = transcatheter aortic valve replacement; Vmax = peak aortic valve velocity. | |||
|} | |||
===Symptomatic, High-Gradient, Severe AS with Associated CAD=== | |||
===Appropriate Use Median Score (1–9)=== | |||
{| class="wikitable" style="width: 80%; text-align: justify;" | |||
! style="width:50%" | '''Indication''' | |||
! style="width:10%" | '''TAVR''' | |||
! style="width:10%" | '''TAVR + PCI''' | |||
! style="width:10%" | '''SAVR''' | |||
! style="width:10%" | '''SAVR + PCI''' | |||
! style="width:10%" | '''SAVR + CABG''' | |||
|- | |||
| - 1- or 2-vessel CAD, no proximal LAD involvement | |||
- High or intermediate surgical risk | |||
| bgcolor="LightGreen" | A (7) || bgcolor="LightGreen" | A (7) || bgcolor="LemonChiffon" | M (4) || bgcolor="LemonChiffon" | M (4) || bgcolor="LightGreen" | A (7) | |||
|- | |||
| - 1- or 2-vessel CAD, no proximal LAD involvement | |||
- Low surgical risk | |||
| bgcolor="LightCoral" | R (3) || bgcolor="LightCoral" | R (3) || bgcolor="LemonChiffon" | M (6) || bgcolor="LemonChiffon" | M (5) || bgcolor="LightGreen" | A (7) | |||
|- | |||
| - 1- or 2-vessel CAD, including LAD involvement | |||
- High or intermediate surgical risk | |||
| bgcolor="LemonChiffon" | M (4) || bgcolor="LightGreen" | A (7) || bgcolor="LightCoral" | R (3) || bgcolor="LemonChiffon" | M (4) || bgcolor="LightGreen" | A (7) | |||
|- | |||
| - 1- or 2-vessel CAD, including LAD involvement | |||
- Low surgical risk | |||
| bgcolor="LightCoral" | R (2) || bgcolor="LightCoral" | R (3) || bgcolor="LightCoral" | R (3) || bgcolor="LightCoral" | R (3) || bgcolor="LightGreen" | A (9) | |||
|- | |||
| - 3-vessel disease; SYNTAX <22 | |||
- High or intermediate surgical risk | |||
| bgcolor="LemonChiffon" | M (4) || bgcolor="LightGreen" | A (7) || bgcolor="LightCoral" | R (3) || bgcolor="LemonChiffon" | M (4) || bgcolor="LightGreen" | A (7) | |||
|- | |||
| - 3-vessel disease; SYNTAX <22 | |||
- Low risk | |||
| bgcolor="LightCoral" | R (2) || bgcolor="LightCoral" | R (3) || bgcolor="LightCoral" | R (2) || bgcolor="LemonChiffon" | M (4) || bgcolor="LightGreen" | A (9) | |||
|- | |||
| - 3-vessel disease; SYNTAX ≥22 | |||
- High or intermediate surgical risk | |||
| bgcolor="LightCoral" | R (3) || bgcolor="LemonChiffon" | M (6) || bgcolor="LightCoral" | R (3) || bgcolor="LemonChiffon" | M (4) || bgcolor="LightGreen" | A (7) | |||
|- | |||
| - 3-vessel disease; SYNTAX ≥22 | |||
- Low surgical risk | |||
| bgcolor="LightCoral" | R (1) || bgcolor="LightCoral" | R (2) || bgcolor="LightCoral" | R (2) || bgcolor="LightCoral" | R (3) || bgcolor="LightGreen" | A (9) | |||
|- | |||
| - Left main; SYNTAX <33 | |||
- High or intermediate surgical risk | |||
| bgcolor="LightCoral" | R (2) || bgcolor="LightGreen" | A (7) || bgcolor="LightCoral" | R (2) || bgcolor="LightCoral" | R (3) || bgcolor="LightGreen" | A (8) | |||
|- | |||
| - Left main; SYNTAX <33 | |||
- Low surgical risk | |||
| bgcolor="LightCoral" | R (1) || bgcolor="LightCoral" | R (2) || bgcolor="LightCoral" | R (2) || bgcolor="LightCoral" | R (3) || bgcolor="LightGreen" | A (9) | |||
|- | |||
| - Left main; SYNTAX ≥33 | |||
- High or intermediate surgical risk | |||
| bgcolor="LightCoral" | R (2) || bgcolor="LemonChiffon" | M (6) || bgcolor="LightCoral" | R (2) || bgcolor="LightCoral" | R (3) || bgcolor="LightGreen" | A (8) | |||
|- | |||
| - Left main; SYNTAX ≥33 | |||
- Low surgical risk | |||
| bgcolor="LightCoral" | R (1) || bgcolor="LightCoral" | R (2) || bgcolor="LightCoral" | R (1) || bgcolor="LightCoral" | R (2) || bgcolor="LightGreen" | A (9) | |||
|- | |||
| colspan="6" | '''A''' = Appropriate; '''AS''' = aortic stenosis; '''AVA''' = aortic valve area; '''CABG''' = coronary artery bypass grafting; '''CAD''' = coronary artery disease; '''LAD''' = left anterior descending; '''M''' = May Be Appropriate; '''PCI''' = percutaneous coronary intervention; '''R''' = Rarely Appropriate; '''SAVR''' = surgical aortic valve replacement; '''SYNTAX''' = synergy between PCI with TAXUS drug-eluting stent and cardiac surgery; '''TAVR''' = transcatheter aortic valve replacement; '''Vmax''' = peak aortic valve velocity. | |||
|} | |||
===Non cardiac Surgery=== | |||
===Appropriate Use Median Score (1–9)=== | |||
{| class="wikitable" style="width: 80%; text-align: justify;" | |||
! style="width:70%" | '''Indication''' | |||
! style="width:10%" | '''No Intervention''' | |||
! style="width:10%" | '''BAV''' | |||
! style="width:10%" | '''AVR (TAVR or SAVR)''' | |||
|- | |||
| - Symptomatic severe / critical AS | |||
- Elective major surgery - Nonobstructive CAD | |||
| bgcolor="LightCoral" | R (1) || bgcolor="LemonChiffon" | M (4) || bgcolor="LightGreen" | A (8) | |||
|- | |||
| - Symptomatic / severe critical AS | |||
- Urgent major surgery - Nonobstructive CAD | |||
| bgcolor="LightCoral" | R (2) || bgcolor="LemonChiffon" | M (6) || bgcolor="LightGreen" | A (7) | |||
|- | |||
| - Asymptomatic severe / critical AS | |||
- Elective major surgery - Nonobstructive CAD | |||
- No signs of cardiac decompensation | |||
| bgcolor="LemonChiffon" | M (4) || bgcolor="LightCoral" | R (3) || bgcolor="LightGreen" | A (7) | |||
|- | |||
| - Asymptomatic severe / critical AS | |||
- Urgent major surgery - Nonobstructive CAD | |||
- No signs of cardiac decompensation | |||
| bgcolor="LemonChiffon" | M (5) || bgcolor="LemonChiffon" | M (4) || bgcolor="LemonChiffon" | M (5) | |||
|- | |||
| colspan="4" | '''A''' = Appropriate; '''AS''' = aortic stenosis; '''AVR''' = aortic valve replacement; '''BAV''' = balloon aortic valvuloplasty; '''CAD''' = coronary artery disease; '''M''' = May Be Appropriate; '''R''' = Rarely Appropriate; '''SAVR''' = surgical aortic valve replacement; '''TAVR''' = transcatheter aortic valve replacement. | |||
|- | |||
| colspan="4" | '''Median Score 1–3:''' Rarely Appropriate care for specific indication (treatment is not generally acceptable and is not a reasonable approach for the indication). '''Median Score 4–6:''' May Be Appropriate care for specific indication (treatment may be generally acceptable and may be a reasonable approach for the indication). '''Median Score 7–9:''' Appropriate care for specific indication (treatment is generally acceptable and is a reasonable approach for the indication). | |||
|} | |} |
Latest revision as of 17:25, 1 November 2017
Template:TAVI - AUC
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1],Associate Editor(s)-in-Chief: Arzu Kalayci, M.D. [2]
ACC/AATS/AHA/ASE/EACTS/ HVS/SCA/SCAI/SCCT/SCMR/STS 2017 Appropriate Use Criteria for the Treatment of Patients With Severe Aortic Stenosis
Asymptomatic, High-Gradient, Severe AS
Appropriate Use Median Score (1–9)
Indication | No Intervention | AVR (TAVR or SAVR) |
---|---|---|
- LVEF ≤50%
- Vmax 4.0–4.9 m/sec - Negative exercise stress test - No predictors of symptom onset or of rapid progression (e.g., DVmax >0.3 m/s/y, severe valve calcification, elevated BNP, or excessive LV hypertrophy in the absence of hypertension) - High or intermediate surgical risk |
A (7) | M (5) |
- LVEF ≤50%
- Vmax 4.0–4.9 m/sec - Negative exercise stress test - No predictors of symptom onset or of rapid progression (e.g., DVmax >0.3 m/s/y, severe valve calcification, elevated BNP, or excessive LV hypertrophy in the absence of hypertension) - Low surgical risk |
A (7) | M (5) |
- LVEF ≥50%
- Vmax 4.0–4.9 m/sec - High-risk profession (e.g., airline pilot) or lifestyle (e.g., competitive athlete) or anticipated prolonged time away from close medical supervision - Low surgical risk |
M (4) | A (7) |
- LVEF ≥50%
- Vmax 4.0–4.9 m/sec - High-risk profession (e.g., airline pilot) or lifestyle (e.g., competitive athlete) or anticipated prolonged time away from close medical supervision - Low surgical risk |
M (4) | A (7) |
- LVEF ≥50%
- Vmax 4.0–4.9 m/sec - Negative exercise stress test - ≥1 predictor(s) of symptom onset or of rapid progression (e.g., DVmax >0.3 m/s/y, severe valve calcification, elevated BNP, or excessive LV hypertrophy in the absence of hypertension) - High or intermediate surgical risk |
M (4) | A (7) |
- LVEF ≥50%
- Vmax 4.0–4.9 m/sec - Negative exercise stress test - ≥1 predictor(s) of symptom onset or of rapid progression (e.g., DVmax >0.3 m/s/y, severe valve calcification, elevated BNP, or excessive LV hypertrophy in the absence of hypertension) - Low surgical risk |
M (4) | A (8) |
- LVEF ≥50%
- Vmax 4.0–4.9 m/sec - Abnormal exercise stress test - High or intermediate surgical risk |
R (3) | A (8) |
- LVEF ≥50%
- Vmax 4.0–4.9 m/sec - Abnormal exercise stress test - Low surgical risk |
R (2) | A (8) |
- LVEF ≥50%
- Very severe AS (Vmax ≥5 m/sec or mean gradient ≥60 mmHg) - High or intermediate surgical risk |
M (4) | A (7) |
- LVEF ≥50%
- Very severe AS (Vmax ≥5 m/sec or mean gradient ≥60 mmHg) - Low surgical risk |
R (2) | A (8) |
- LVEF <50%
- Very severe AS (Vmax ≥4 m/sec or mean gradient ≥40 mmHg) - High or intermediate surgical risk |
R (2) | A (8) |
- LVEF <50%
- Very severe AS (Vmax ≥4 m/sec or mean gradient ≥40 mmHg) - Low surgical risk |
R (1) | A (9) |
- Undergoing another cardiac surgery or ascending aortic surgery | R (1) | A (9) |
A = Appropriate; AS = aortic stenosis; AVR = aortic valve replacement; BNP = b-type natriuretic peptide; LV = left ventricular/left ventricle; LVEF = left ventricular ejection fraction; M = May Be Appropriate; R = Rarely Appropriate; SAVR = surgical aortic valve replacement; TAVR = transcatheter aortic valve replacement; Vmax = peak aortic valve velocity. |
Flow, Gradient and Ejection Fraction
Appropriate Use Median Score (1–9)
Indication | No Intervention | BAV (as Bridge to Decision) | AVR (TAVR or SAVR) |
---|---|---|---|
Reduced Ejection Fraction (<50%) | |||
- AVA ≤1.0 cm2 (or indexed AVA ≤0.6 cm2/m2) on resting echo
- LVEF 20% to 49% - Low flow - Low gradient - Flow reserve on low-dose dobutamine echo - Truly severe AS - High or intermediate surgical risk |
R (1) | R (3) | A (8) |
- AVA ≤1.0 cm2 (or indexed AVA ≤0.6 cm2/m2) on resting echo
- LVEF 20% to 49% - Low flow - Low gradient - Flow reserve on low-dose dobutamine echo - Truly severe AS - Low surgical risk |
R (1) | R (2) | A (9) |
- AVA ≤1.0 cm2 (or indexed AVA ≤0.6 cm2/m2) on resting echo
- LVEF 20% to 49% - Low flow - Low gradient - Flow reserve on low-dose dobutamine echo - Pseudosevere AS |
A (8) | R (2) | R (2) |
- AVA ≤1.0 cm2 (or indexed AVA ≤0.6 cm2/m2) on resting echo
- LVEF 20% to 49% - Low flow - Low gradient - No flow reserve on low-dose dobutamine echo - Very calcified aortic valve on echo and/or CT, suggesting truly severe AS, or calculation of a projected valve area that remains severely reduced - High or intermediate surgical risk |
M (4) | M (5) | A (7) |
- AVA ≤1.0 cm2 (or indexed AVA ≤0.6 cm2/m2) on resting echo
- LVEF 20% to 49% - Low flow - Low gradient - No flow reserve on low-dose dobutamine echo - Minimal calcification on aortic valve on echo and/or CT - High or intermediate surgical risk |
A (7) | R (3) | R (2) |
- AVA ≤1.0 cm2 (or indexed AVA ≤0.6 cm2/m2)
- LVEF <20% - Vmax ≥4 m/sec or mean gradient ≥40 mmHg on resting echo - High or intermediate surgical risk |
R (3) | M (4) | A (7) |
- AVA ≤1.0 cm2 (or indexed AVA ≤0.6 cm2/m2)
- LVEF <20% - Mean gradient <20 mmHg on resting echo - No flow reserve on low-dose dobutamine echo - High or intermediate surgical risk |
A (7) | M (4) | R (3) |
- AVA ≤1.0 cm2 (or indexed AVA ≤0.6 cm2/m2) on resting echo
- LVEF <20% - Low flow - Low gradient - Flow reserve on low-dose dobutamine echo - Truly severe AS - High or intermediate surgical risk |
R (3) | M (5) | A (7) |
- AVA ≤1.0 cm2 (or indexed AVA ≤0.6 cm2/m2) on resting echo
- LVEF <20% - Low flow - Low gradient - Flow reserve on low-dose dobutamine echo - Pseudosevere severe AS - High or intermediate surgical risk |
A (7) | R (2) | R (2) |
Preserved Ejection Fraction (≥50%) | |||
- AVA ≤1.0 cm2 (or indexed AVA ≤0.6 cm2/m2)
- Vmax ≥4 m/sec or mean gradient ≥40 mmHg on resting echo - Symptomatic - High or intermediate surgical risk |
R (1) | R (2) | A (9) |
- AVA ≤1.0 cm2 (or indexed AVA ≤0.6 cm2/m2)
- Vmax ≥4 m/sec or mean gradient ≥40 mmHg on resting echo - Symptomatic - Low surgical risk |
R (1) | R (1) | A (9) |
- AVA ≤1.0 cm2 (or indexed AVA ≤0.6 cm2/m2)
- Low flow - Low gradient - Symptomatic - Evidence of a severely calcified valve - Clinical, hemodynamic, and anatomic data support valve obstruction as the most likely cause of symptoms - High or intermediate surgical risk |
R (2) | R (3) | A (8) |
- AVA ≤1.0 cm2 (or indexed AVA ≤0.6 cm2/m2)
- Low flow - Low gradient - Symptomatic - Evidence of a severely calcified valve - Clinical, hemodynamic, and anatomic data support valve obstruction as the most likely cause of symptoms - Low surgical risk |
R (1) | R (1) | A (9) |
- AVA ≤1.0 cm2 (or indexed AVA ≤0.6 cm2/m2)
- Low flow - Low gradient - Evidence of a severely calcified valve - Asymptomatic - High or intermediate surgical risk |
M (6) | R (3) | M (4) |
- AVA ≤1.0 cm2 (and indexed AVA ≤0.6 cm2/m2)
- Low gradient - Low flow - Evidence of a severely calcified valve - Asymptomatic - Low surgical risk |
M (6) | R (2) | M (4) |
- AVA ≤1.0 cm2 (and indexed AVA ≤0.6 cm2/m2)
- Normal flow - Low gradient - Confirmation of internal consistency of the AVA, flow, and gradient measurements - Evidence of a severely calcified valve - Symptoms believed to be due to AS - High or intermediate surgical risk |
R (3) | M (4) | A (7) |
- AVA ≤1.0 cm2 (and indexed AVA ≤0.6 cm2/m2)
- Normal flow - Low gradient - Confirmation of internal consistency of the AVA, flow, and gradient measurements - Evidence of a severely calcified valve - Symptoms believed to be due to AS - Low surgical risk |
R (3) | R (3) | A (7) |
A = Appropriate; AS = aortic stenosis; AVA = aortic valve area; AVR = aortic valve replacement; BAV = balloon aortic valvuloplasty; CT = computed tomography; LVEF = left ventricular ejection fraction; M = May Be Appropriate; R = Rarely Appropriate; SAVR = surgical aortic valve replacement; TAVR = transcatheter aortic valve replacement; Vmax = peak aortic valve velocity. |
Severe AS: High- or Extreme-Risk Patients
Appropriate Use Median Score (1–9)
Indication | No Intervention | BAV (as Bridge to Decision) | TAVR | SAVR |
---|---|---|---|---|
Due to Multiple Comorbidities | ||||
- Severe symptomatic AS
- STS-PROM 8%–15% - Health status seems to be influenced more by comorbidities than by AS - Anticipated life expectancy >1 y |
M (4) | M (5) | A (7) | M (4) |
- Severe symptomatic AS
- STS-PROM 8%–15% - Health status seems to be influenced more by AS than by comorbidities - Anticipated life expectancy >1 y |
R (2) | M (4) | A (8) | M (5) |
- Severe symptomatic AS
- STS-PROM 8%–15% - Health status seems to be influenced more by comorbidities than by AS - Anticipated life expectancy <1 y |
A (8) | M (5) | R (3) | R (1) |
- Severe symptomatic AS
- STS-PROM 8%–15% - Health status seems to be influenced more by AS than by comorbidities - Anticipated life expectancy <1 y |
M (6) | M (5) | M (4) | R (2) |
- Severe symptomatic AS
- STS-PROM >15% - Health status seems to be influenced more by comorbidities than by AS - Anticipated life expectancy >1 y |
M (6) | M (5) | M (6) | R (2) |
- Severe symptomatic AS
- STS-PROM >15% - Health status seems to be influenced more by AS than by comorbidities - Anticipated life expectancy >1 y |
M (4) | M (5) | A (7) | R (3) |
- Severe symptomatic AS
- STS-PROM >15% - Health status seems to be influenced more by comorbidities than by AS - Anticipated life expectancy <1 y |
A (8) | M (4) | R (3) | R (1) |
- Severe symptomatic AS
- STS-PROM >15% - Health status seems to be influenced more by AS than by comorbidities - Anticipated life expectancy <1 y |
A (7) | M (5) | R (3) | R (1) |
With Frailty or Disability | ||||
- Severe AS (Vmax 4–4.9 m/s)
- STS-PROM 8%–15% - Frail - No chest pain or syncope - Fatigue but no shortness of breath - Normal BNP |
M (5) | M (4) | M (5) | R (3) |
- Severe AS (Vmax 4–4.9 m/s)
- STS-PROM 8%–15% - Frail - No chest pain or syncope - Fatigue but no shortness of breath - BNP elevated |
M (4) | M (4) | A (7) | M (4) |
- Severe AS (Vmax ≥5 m/s)
- STS-PROM 8%–15% - Frail - No chest pain or syncope - Fatigue but no shortness of breath - Normal BNP |
M (4) | M (5) | A (7) | M (4) |
- Severe AS (Vmax ≥5 m/s)
- STS-PROM 8%–15% - Frail - No chest pain or syncope - Fatigue but no shortness of breath - BNP elevated |
R (3) | M (5) | A (8) | M (4) |
- Severe AS (Vmax ≥4 m/s)
- STS-PROM 8%-15% - Dependent in >3 activities of daily living (bathing, dressing, eating, ambulating, toileting, transferring) - Shortness of breath |
M (5) | M (5) | M (5) | R (2) |
- Severe AS (Vmax ≥4 m/s)
- STS-PROM 8%-15% - Dependent in >3 activities of daily living (bathing, dressing, eating, ambulating, toileting, transferring) - Fatigue but no shortness of breath |
M (5) | M (5) | M (5) | R (2) |
Due to Anatomy | ||||
- Severe symptomatic AS
- Porcelain aorta or hostile chest - Otherwise high or intermediate surgical risk due to comorbidities |
R (2) | M (4) | A (8) | R (3) |
- Severe symptomatic AS
- Porcelain aorta or hostile chest - Otherwise low surgical risk due to comorbidities |
R (1) | R (3) | A (8) | M (4) |
Due to Specific Comorbidities | ||||
- Severe AS
- STS-PROM 8%–15% - Oxygen-dependent lung disease - Shortness of breath - BNP normal |
M (5) | M (5) | A (7) | R (3) |
- Severe AS
- STS-PROM 8%–15% - Oxygen-dependent lung disease - Shortness of breath - BNP elevated |
R (3) | M (5) | A (8) | M (4) |
- Severe symptomatic AS
- STS-PROM >15% - End-stage renal disease - Longstanding dialysis, not a renal transplant candidate - Multiple comorbidities |
M (5) | M (4) | M (6) | R (2) |
- Severe symptomatic AS
- STS-PROM 8%–15% - End-stage renal disease - Short time on dialysis - Renal transplant candidate - Nondiabetic, nonhypertensive ethology |
R (3) | R (3) | A (7) | A (7) |
- Severe symptomatic AS
- STS-PROM 8%–15% - Cirrhosis with MELD >14 |
M (5) | M (5) | A (7) | R (2) |
- Severe symptomatic AS
- STS-PROM 8%–15% - Cirrhosis with MELD <10 |
R (3) | M (4) | A (7) | M (5) |
- Severe symptomatic AS
- STS-PROM 8%–15% - Moderate to severe dementia (minimally oriented) - Symptoms described by family but not verbalized by the patient |
A (8) | R (3) | R (2) | R (1) |
- Severe symptomatic AS
- STS-PROM 8%–15% - Malignancy - Life expectancy >1 year |
M (5) | M (4) | A (7) | M (6) |
- Severe symptomatic AS
- STS-PROM 8%–15% - Malignancy - Life expectancy <1 year |
A (7) | M (5) | R (2) | R (1) |
A = Appropriate; AS = aortic stenosis; BAV = balloon aortic valvuloplasty; BNP = b-type natriuretic peptide; M = May Be Appropriate; MELD = model for end-stage liver disease; R = Rarely Appropriate; SAVR = surgical aortic valve replacement; STS-PROM = Society of Thoracic Surgeons predicted risk of mortality score; TAVR = transcatheter aortic valve replacement; Vmax = peak aortic valve velocity. |
Symptomatic, High-Gradient, Severe AS with Associated CAD
Appropriate Use Median Score (1–9)
Indication | TAVR | TAVR + PCI | SAVR | SAVR + PCI | SAVR + CABG |
---|---|---|---|---|---|
- 1- or 2-vessel CAD, no proximal LAD involvement
- High or intermediate surgical risk |
A (7) | A (7) | M (4) | M (4) | A (7) |
- 1- or 2-vessel CAD, no proximal LAD involvement
- Low surgical risk |
R (3) | R (3) | M (6) | M (5) | A (7) |
- 1- or 2-vessel CAD, including LAD involvement
- High or intermediate surgical risk |
M (4) | A (7) | R (3) | M (4) | A (7) |
- 1- or 2-vessel CAD, including LAD involvement
- Low surgical risk |
R (2) | R (3) | R (3) | R (3) | A (9) |
- 3-vessel disease; SYNTAX <22
- High or intermediate surgical risk |
M (4) | A (7) | R (3) | M (4) | A (7) |
- 3-vessel disease; SYNTAX <22
- Low risk |
R (2) | R (3) | R (2) | M (4) | A (9) |
- 3-vessel disease; SYNTAX ≥22
- High or intermediate surgical risk |
R (3) | M (6) | R (3) | M (4) | A (7) |
- 3-vessel disease; SYNTAX ≥22
- Low surgical risk |
R (1) | R (2) | R (2) | R (3) | A (9) |
- Left main; SYNTAX <33
- High or intermediate surgical risk |
R (2) | A (7) | R (2) | R (3) | A (8) |
- Left main; SYNTAX <33
- Low surgical risk |
R (1) | R (2) | R (2) | R (3) | A (9) |
- Left main; SYNTAX ≥33
- High or intermediate surgical risk |
R (2) | M (6) | R (2) | R (3) | A (8) |
- Left main; SYNTAX ≥33
- Low surgical risk |
R (1) | R (2) | R (1) | R (2) | A (9) |
A = Appropriate; AS = aortic stenosis; AVA = aortic valve area; CABG = coronary artery bypass grafting; CAD = coronary artery disease; LAD = left anterior descending; M = May Be Appropriate; PCI = percutaneous coronary intervention; R = Rarely Appropriate; SAVR = surgical aortic valve replacement; SYNTAX = synergy between PCI with TAXUS drug-eluting stent and cardiac surgery; TAVR = transcatheter aortic valve replacement; Vmax = peak aortic valve velocity. |
Non cardiac Surgery
Appropriate Use Median Score (1–9)
Indication | No Intervention | BAV | AVR (TAVR or SAVR) |
---|---|---|---|
- Symptomatic severe / critical AS
- Elective major surgery - Nonobstructive CAD |
R (1) | M (4) | A (8) |
- Symptomatic / severe critical AS
- Urgent major surgery - Nonobstructive CAD |
R (2) | M (6) | A (7) |
- Asymptomatic severe / critical AS
- Elective major surgery - Nonobstructive CAD - No signs of cardiac decompensation |
M (4) | R (3) | A (7) |
- Asymptomatic severe / critical AS
- Urgent major surgery - Nonobstructive CAD - No signs of cardiac decompensation |
M (5) | M (4) | M (5) |
A = Appropriate; AS = aortic stenosis; AVR = aortic valve replacement; BAV = balloon aortic valvuloplasty; CAD = coronary artery disease; M = May Be Appropriate; R = Rarely Appropriate; SAVR = surgical aortic valve replacement; TAVR = transcatheter aortic valve replacement. | |||
Median Score 1–3: Rarely Appropriate care for specific indication (treatment is not generally acceptable and is not a reasonable approach for the indication). Median Score 4–6: May Be Appropriate care for specific indication (treatment may be generally acceptable and may be a reasonable approach for the indication). Median Score 7–9: Appropriate care for specific indication (treatment is generally acceptable and is a reasonable approach for the indication). |